BridgeBio Pharma, Inc.
BBIONasdaqCIK 1743881HealthcareFiscal year ends Dec 31
Reports and events: 183 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2024-11-1207:32 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-124577 |
| 2024-11-1207:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-124576 |
| 2024-11-0617:04 ET | SC 13D/A | Ownership report, active investor, amended | 0000905148-24-002952 |
| 2024-09-1718:41 ET | SC 13D/A | Ownership report, active investor, amended | 0001140361-24-041327 |
| 2024-09-1118:23 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-24-040755 |
| 2024-08-2020:42 ET | SC 13D/A | Ownership report, active investor, amended | 0001140361-24-037981 |
| 2024-08-2120:16 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001140361-24-037974 |
| 2024-08-0116:24 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-089326 |
| 2024-08-0107:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-088952 |
| 2024-07-2316:12 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-24-033856 |
| 2024-06-2416:01 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001140361-24-031087 |
| 2024-06-0606:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-24-029050 |
| 2024-05-0216:24 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-052165 |
| 2024-05-0207:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-051573 |
| 2024-04-2516:01 ET | DEF 14A | Proxy statementPeriod 2024-06-21 | 0001140361-24-022023 |
| 2024-03-0617:13 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-24-011766 |
| 2024-03-0407:00 ET | 8-K | 1.01 Entry into a material agreement | 0001140361-24-010920 |
| 2024-02-2216:27 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-018811 |
| 2024-02-2207:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-018431 |
| 2024-01-1807:30 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation | 0001140361-24-002636 |
| 2024-01-0817:14 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-24-001358 |
| 2023-11-2216:15 ET | SC 13D/A | Ownership report, active investor, amended | 0001140361-23-054445 |
| 2023-11-0216:23 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-058255 |
| 2023-11-0207:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-057745 |
| 2023-09-2516:00 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-23-049683 |
| 2023-08-0316:12 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-037977 |
| 2023-08-0307:32 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-037590 |
| 2023-07-2021:52 ET | SC 13D/A | Ownership report, active investor, amended | 0001140361-23-035291 |
| 2023-07-1707:23 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-23-034684 |
| 2023-06-2216:05 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001140361-23-030932 |
| 2023-05-0417:18 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001193125-23-136095 |
| 2023-05-0416:01 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-017812 |
| 2023-05-0407:46 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-135073 |
| 2023-04-2816:39 ET | DEF 14A | Proxy statement | 0001193125-23-127256 |
| 2023-03-0909:02 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-065459 |
| 2023-03-0609:09 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-060828 |
| 2023-02-2316:32 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-004145 |
| 2023-02-2307:51 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-23-045663 |
| 2022-12-0617:04 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-22-299475 |
| 2022-11-0317:05 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-277008 |
| 2022-11-0316:33 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-021936 |
| 2022-09-2316:18 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-250165 |
| 2022-08-0416:46 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-014824 |
| 2022-08-0416:43 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-212597 |
| 2022-07-2608:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-201502 |
| 2022-06-2416:29 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-22-181550 |
| 2022-05-1816:02 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-22-154023 |
| 2022-05-1316:32 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-22-150167 |
| 2022-05-1017:24 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-22-146467 |
| 2022-05-0516:32 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-007874 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 3, 2026, 19:31 ET. Listed shows no prices and gives no investment advice.